Zoetis Inc. (NYSE:ZTS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Zoetis Inc. (NYSE:ZTS) have been given an average rating of “Moderate Buy” by the twelve analysts that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $178.8889.

A number of equities research analysts recently weighed in on the company. Argus reaffirmed a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. KeyCorp assumed coverage on shares of Zoetis in a research report on Thursday, November 20th. They set a “sector weight” rating for the company. Morgan Stanley lowered their price target on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a report on Monday, November 10th. BTIG Research reiterated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research note on Wednesday. Finally, JPMorgan Chase & Co. decreased their target price on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th.

Zoetis Stock Performance

Shares of ZTS stock opened at $120.33 on Friday. The firm has a market cap of $53.03 billion, a price-to-earnings ratio of 20.26, a PEG ratio of 2.54 and a beta of 0.97. Zoetis has a 52-week low of $115.25 and a 52-week high of $181.85. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The company’s 50 day moving average is $134.27 and its 200 day moving average is $148.09.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. During the same quarter last year, the firm earned $1.58 EPS. The business’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts anticipate that Zoetis will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st were issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.7%. The ex-dividend date was Friday, October 31st. Zoetis’s dividend payout ratio is currently 33.67%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZTS. Savvy Advisors Inc. increased its holdings in Zoetis by 54.0% during the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock valued at $495,000 after acquiring an additional 1,114 shares in the last quarter. Sound Income Strategies LLC lifted its holdings in shares of Zoetis by 54.3% in the second quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after purchasing an additional 152 shares in the last quarter. Canoe Financial LP increased its stake in shares of Zoetis by 859.0% during the 2nd quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock worth $2,085,000 after purchasing an additional 11,975 shares in the last quarter. Strs Ohio acquired a new position in shares of Zoetis during the 1st quarter worth approximately $22,891,000. Finally, Chicago Partners Investment Group LLC lifted its stake in Zoetis by 67.0% in the 2nd quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock valued at $750,000 after buying an additional 1,961 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.